Quigley announces interim CEO
DOYLESTOWN, Pa. The Quigley Corp. on Thursday announced that Quigley chairman Ted Karkus has been appointed interim CEO by the board.
Karkus will serve in this role effective June 18, and will be compensated at a rate of $5,000 per week for his services.
The news came one week after Guy Quigley announced his resignation as chairman, president and CEO of the company. The resignation followed a proxy contest, which culminated on May 20 at the company’s annual meeting, that favored shareholder Ted Karkus and his proposed slate of directors. Quigley Corp. also accepted the resignation of Charles Phillips, COO, and Wendy Quigley, accounting operations manager.
“Despite everything that has been said and done during the course of this proxy contest, my goal has been, and continues [to be], to build stockholder value,” Quigley stated. “I am very proud of our work over the past 20 years. Cold-Eeze is a highly respected product and well-established household name, and Quigley Pharma has several compounds that have reached a point of value inflection,” he said.
NPA criticizes remarks tying dietary supplements to tainted products
WASHINGTON The Natural Products Association on Thursday released a statement criticizing the erroneous link between legitimate dietary supplements and tainted products. “Increased scrutiny by professional sports leagues on steroid usage, which the Natural Products Association commends, has unfortunately also led to increased and unsubstantiated allegations that a ‘tainted’ or mislabeled dietary supplement is to blame when an athlete tests positive for a banned substance,” said David Seckman, NPA executive director and CEO.
“As the Dietary Supplement Health and Education Act of 1994 mandates, all ingredients must be listed on product labels and product claims must be substantiated. If this is not the case, the U.S. Food and Drug Administration—along with the Federal Trade Commission—have the authority under DSHEA to act promptly,” he said.
Seckman also noted that not all substances banned by professional sports organizations as performance enhancers are either bad or illegal. “Performance enhancers [that] are not necessarily dangerous or illegal … include caffeine, commonly used over-the-counter cold remedies and prescription medications,” he said. “Athletes have the right and responsibility to avoid their use. However, the consuming public who benefits from legitimate medications or dietary supplements – as well as a trip to the local coffee house – should not be denied their use if an athlete is unwilling or unable to follow the rules established by their sport.”
Consumer Healthcare Products names Kochanowski VP regulatory affairs
WASHINGTON The Consumer Healthcare Products Association on Wednesday named Barbara Kochanowski as VP, regulatory affairs.
In this new role, Kochanowski will team up with CHPA’s Heinz Schneider, vice president, science and medical affairs, to ensure and expand the availability of consumer healthcare products to American families and to work with the association’s key stakeholders in this effort.
“[Kochanowski’s] wealth of experience and established relationships with professionals throughout our industry have gained her well-deserved respect and appreciation,” stated Linda Suydam, CHPA president. “We are pleased to have someone with her deepened regulatory expertise join our effort to promote the safe and responsible use of consumer healthcare therapies as the dynamics of our industry evolve.”
Prior to joining CHPA, Kochanowski worked with the association for many years through her role as director, global personal health, oral care and feminine care product safety and regulatory affairs, at the Procter & Gamble Company, where she was responsible for global expansion of over-the-counter healthcare medicines and medical devices.
Most recently, she served as chair of the association’s Scientific Affairs Committee and a member of CHPA’s Board of Directors. Kochanowski holds her PhD from the University of Illinois. She is a native of Beaver, Pa.